Skip to main content

Alexion enters RNA gene-silencing field with $637M Dicerna deal

Newly Massachusetts-based biotech Alexion Pharmaceuticals became the latest company to enter the gene silencing drug field, signing a deal with Dicerna Pharmaceuticals worth upwards of $637 million.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.